APA (7th ed.) Citation

Ji, D., Luo, Y., Wang, J., Chen, S., Lan, B., Ma, F., . . . Fan, Y. (2023). CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: A network meta-analysis. BMC Cancer, 23(1), 1. https://doi.org/10.1186/s12885-023-11290-7

Chicago Style (17th ed.) Citation

Ji, Danyang, Yang Luo, Jiayu Wang, Shanshan Chen, Bo Lan, Fei Ma, Binghe Xu, and Ying Fan. "CDK4/6 Inhibitors, PI3K/mTOR Inhibitors, and HDAC Inhibitors as Second-line Treatments for Hormone Receptor-positive, HER2-negative Advanced Breast Cancer: A Network Meta-analysis." BMC Cancer 23, no. 1 (2023): 1. https://doi.org/10.1186/s12885-023-11290-7.

MLA (9th ed.) Citation

Ji, Danyang, et al. "CDK4/6 Inhibitors, PI3K/mTOR Inhibitors, and HDAC Inhibitors as Second-line Treatments for Hormone Receptor-positive, HER2-negative Advanced Breast Cancer: A Network Meta-analysis." BMC Cancer, vol. 23, no. 1, 2023, p. 1, https://doi.org/10.1186/s12885-023-11290-7.